The Effect of a High‐Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma
Authors:
Open Access
- 17 March 2016
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 56 (10) , 1288-1295
Abstract
Ixazomib is the first oral proteasome inhibitor to be investigated in the clinic. This clinical study assessed whether the pharmacokinetics of ixazomib would be altered if administered after a high‐calorie, high‐fat meal. In a 2‐period, 2‐sequence, crossover study design, adult patients with advanced solid tumors or lymphoma received a 4‐mg oral dose of ixazomib as immediate‐release capsules on day 1 without food (fasted, administered following an overnight fast) or with food (fed, following consumption of a high‐calorie, high‐fat meal), followed by another dose on day 15 in the alternate food intake condition (fasted to fed or fed to fasted). Twenty‐four patients were enrolled; of these, 15 were included in the pharmacokinetic‐evaluable population. Administration of ixazomib after a high‐fat meal reduced both the rate and extent of absorption of ixazomib. Under fed conditions, the median time to peak plasma concentration (Tmax) of ixazomib was delayed by approximately 3 hours compared with administration in the fasted state (1.02 hours vs 4.0 hours), and there was a 28% reduction in total systemic exposure (area under the curve, AUC) and a 69% reduction in peak plasma concentration (Cmax). Together, the results support the administration of ixazomib on an empty stomach, at least 1 hour before or at least 2 hours after food. These recommendations are reflected in the United States Prescribing Information for ixazomib (clinicaltrials.gov identifier NCT01454076).Keywords
Funding Information
- Millennium Pharmaceuticals, Cambridge, MA
This publication has 20 references indexed in Scilit:
- Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell MalignanciesClinical Cancer Research, 2011
- In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma CellsClinical Cancer Research, 2011
- Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human CancerCancer Research, 2010
- Effects of Food on the Relative Bioavailability of Lapatinib in Cancer PatientsJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorptionAdvanced Drug Delivery Reviews, 2008
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- A phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBritish Journal of Haematology, 2004
- Effects of Food on the Clinical Pharmacokinetics of Anticancer AgentsClinical Pharmacokinetics, 2004
- A Phase 2 Study of Bortezomib in Relapsed, Refractory MyelomaNew England Journal of Medicine, 2003